Perhaps the report on China’s strategy for eclipsing the U.S. lead in biopharma from the Information Technology & Innovation Foundation (ITIF) resonated so strongly with me because of several articles in The Wall Street Journal. Taken together, they present a sobering picture of what we’re up against. The first was a book review of “Leadership and the Rise of Great Powers” by Yan Xuetong, a prominent Chinese professor. Characterized as “a window into Chinese elite thinking about the world; it is as much a political manual as an international-relations text book.” The thesis is the inevitable rise of China as the world’s dominant power at the expense of the United States.
Recent Posts
- Novartis’ Entresto Patent Claims Revived by CAFC
- INTA Urges EUIPO Grand Board to Confirm Human Face Marks are Not Excluded from Trademark Registration
- New USPTO Fee Rule for Continuing Applications: Key Changes and Strategic Considerations for Applicants
- AI and the Level of Ordinary Skill: Why Patent Law Must (and Can) Adapt to AI-Augmented Invention
- Federal Circuit Upholds PTAB Win for Patent to Detect Genetic Disorders